Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 17/20 | 0.54 |
| ▸ | PPARA | Q07869 | 12/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381740 | 0.85 | PPARD (0.43) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5376727 | 0.83 | FFAR1 (0.65) | FFAR1PPARGPPARA | |
| SCHEMBL7539449 | 0.83 | PPARG (0.53) | FFAR1PPARGPPARA | |
| SCHEMBL5376844 | 0.83 | FFAR1 (0.72) | FFAR1PPARGPPARA | |
| SCHEMBL6591860 | 0.83 | FFAR1 (0.61) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5377340 | 0.82 | FFAR1 (0.60) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5380550 | 0.80 | FFAR1 (0.69) | FFAR1PPARGPPARA | |
| SCHEMBL5376899 | 0.78 | FFAR1 (0.60) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5381904 | 0.77 | FFAR1 (0.62) | FFAR1PPARGPPARA | |
| SCHEMBL5387534 | 0.75 | FFAR1 (0.70) | FFAR1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228067-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001038325-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-31 | — | — | WO | disclosed |